The Korean journal of internal medicine

  • 제29권1호
  • /
  • Pages.23-26
  • /
  • 2014
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Risks associated with sunitinib use and monitoring to improve patient outcomes

  • Choi, Bum Soon (Division of Nephrology, Department of Internal Medicine, The Catholic University of Korea College of Medicine)
  • 투고 : 2013.12.12
  • 심사 : 2013.12.16
  • 발행 : 2014.01.01
⟨ 이전 논문 다음 논문 ⟩

초록

키워드

참고문헌

  1. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358:2039-2049. https://doi.org/10.1056/NEJMra0706596
  2. Zhou A. Management of sunitinib adverse events in renal cell carcinoma patients: the Asian experience. Asia Pac J Clin Oncol 2012;8:132-144. https://doi.org/10.1111/j.1743-7563.2012.01525.x
  3. Sivendran S, Liu Z, Portas LJ Jr, et al. Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis. Cancer Treat Rev 2012;38:919-925. https://doi.org/10.1016/j.ctrv.2012.05.001
  4. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-1338. https://doi.org/10.1016/S0140-6736(06)69446-4
  5. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-124. https://doi.org/10.1056/NEJMoa065044
  6. Mendez-Vidal MJ, Martinez Ortega E, Montesa Pino A, Perez Valderrama B, Viciana R. Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma. Cancer Metastasis Rev 2012;31 Suppl 1:S19-S27. https://doi.org/10.1007/s10555-012-9355-y
  7. Rini BI, Tamaskar I, Shaheen P, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007;99:81-83. https://doi.org/10.1093/jnci/djk008
  8. Baek SH, Kim H, Lee J, et al. Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea. Korean J Intern Med 2014;29:40-48. https://doi.org/10.3904/kjim.2014.29.1.40
  9. Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC. VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 2010;46:439-448. https://doi.org/10.1016/j.ejca.2009.11.001
  10. Tryggvason K, Patrakka J, Wartiovaara J. Hereditary proteinuria syndromes and mechanisms of proteinuria. N Engl J Med 2006;354:1387-1401. https://doi.org/10.1056/NEJMra052131
  11. Orphanos GS, Ioannidis GN, Ardavanis AG. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol 2009;48:964-970. https://doi.org/10.1080/02841860903229124
  12. Kumar R, Crouthamel MC, Rominger DH, et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 2009;101:1717-1723. https://doi.org/10.1038/sj.bjc.6605366
  13. Wolter P, Stefan C, Decallonne B, et al. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer 2008;99:448-454. https://doi.org/10.1038/sj.bjc.6604497
  14. Wong E, Rosen LS, Mulay M, et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 2007;17:351-355. https://doi.org/10.1089/thy.2006.0308
  15. Tamaskar I, Bukowski R, Elson P, et al. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol 2008;19:265-268. https://doi.org/10.1093/annonc/mdm483
  16. Lacouture ME, Wu S, Robert C, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008;13:1001-1011. https://doi.org/10.1634/theoncologist.2008-0131
  17. Lammie A, Drobnjak M, Gerald W, Saad A, Cote R, Cordon- Cardo C. Expression of c-kit and kit ligand proteins in normal human tissues. J Histochem Cytochem 1994;42:1417-1425. https://doi.org/10.1177/42.11.7523489
  18. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-3590. https://doi.org/10.1200/JCO.2008.20.1293
  19. Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded- access trial. Lancet Oncol 2009;10:757-763. https://doi.org/10.1016/S1470-2045(09)70162-7